Brief: Herantis Pharma elaborates on its outlook for 2016
04/01/2016 07:01
Jan 4 (Reuters) - Herantis Pharma Oyj HRTIS.HE :
* Completed a randomized Phase 2 clinical study in 2015 with its cis-UCA Eye Drops in
patients with Dry Eye as disclosed by a company release June 3, 2015
* The study failed to meet the primary endpoints
* Continues discussions for a potential co-development partnership in 2016
* Continues preparations of a first-in-human clinical study with CDNF in Parkinson's disease
as planned
* Maintains its previously disclosed target to start patient recruitment in this Phase 1
clinical study in H1 2016
* Maintains its previous target of announcing at least one commercialization agreement
related to its drug candidates by the end of 2017
Source text for Eikon: ID:nHUGbcGb62
Further company coverage: HRTIS.HE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48586983920;))